發稿單位：Reuters 發稿時間：FEBRUARY 4, 2020 / 9:56 PM 撰 稿 者：Manas Mishra 原文連結：https://reut.rs/2GQOpza 摘要: 美國衛生部 HSS 周二宣布將與再生元製藥 (Regeneron Pharmaceuticals, REGN) 合作開發新型冠狀病毒的療法。REGN 在 2017年曾與 HHS 合作開發對抗伊波拉病 毒的藥物。 REGN 表示她們將專注於開發對抗感染的單株抗體 (monoclonal antibodies)。 除 REGN 外，目前已有 Moderna, Gilead, Johnson & Johnson 宣布將投入開發對 抗新型冠狀病毒的藥物。 (Reuters) - The U.S. Department of Health and Human Services said on Tuesday it was partnering with Regeneron Pharmaceuticals Inc (REGN.O) to develop a treatment for the coronavirus, making the drugmaker the latest to join the race to develop a therapy. The move expands on a previous agreement with the company in 2017 to develop treatments for pathogens that pose significant risk to the public. Regeneron had partnered with an HHS unit to develop treatments for Ebola in 2017. The drugmaker will use the same technology that was used to develop an experimental drug to treat Ebola in the Democratic Republic of Congo, the agency said. Regeneron said it would focus on developing infection-fighting proteins known as monoclonal antibodies. Moderna Inc (MRNA.O), Gilead Sciences Inc (GILD.O), Johnson & Johnson (JNJ.N) have also announced plans to begin work on a treatment for the outbreak, which has affected over 20,000 people in China. --

※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 1.169.215.121 (臺灣) ※ 文章網址: https://webptt.com/m.aspx?n=bbs/nCoV2019/M.1580827505.A.847.html